Johnson & Johnson sales
This article was originally published in The Tan Sheet
Executive Summary
J&J's acquisition of Merck's stake in the European nonprescription joint venture drove 17% jump in second quarter operational growth for the firm's McNeil OTC and nutritional franchise compared with the year-ago quarter, the firm announces in a July 13 analysts call. The new McNeil Europe subsidiary will handle the launch of Zocor Heart-Pro nonprescription statin in the UK (1"The Tan Sheet" April 26, 2004, p. 6). International consumer product sales grew 14.1%, or 9%, excluding the impact of currency exchange, to $1.01 bil., compared with the second quarter of 2003. U.S. consumer sales grew 6% to $987 mil., with worldwide consumer sales totaling $2 bil., up 7.5 % excluding currency exchange...
You may also be interested in...
J&J Buyout Of Merck Stake In Europe Was In The Works “For Some Time”
Retaining rights to future Rx-to-OTC switches and a substantial one-time cash infusion were the major drivers of Merck's decision to sell its 50% stake of an OTC venture in Europe to partner Johnson & Johnson
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.